Financials Oscotec Inc.

Equities

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
30,200 ^KRW	+5.96%		-3.05%	+31.02%

Feb. 23	Oscotec/Adel Initiates First-In-Human Dosing in Ph1 of Anti-Mtbr Tau Antibody Adel-Y01 in Alzheimer's Disease	CI
2023	Oscotec Inc. and ADEL Inc. Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's Disease	CI

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	714,757	1,970,207	1,110,134	655,533	880,167	1,153,493	-	-
Enterprise Value (EV) ²	714.8	1,944	1,102	655.5	880.2	1,060	1,026	1,028
P/E ratio	-27.1 x	-423 x	-	-22.7 x	-	-	-	-
Yield	-	-	-	-	-	-	-	-
Capitalization / Revenue	164 x	45.3 x	284 x	-	178 x	26.2 x	16.6 x	16.2 x
EV / Revenue	164 x	44.7 x	282 x	-	178 x	24.1 x	14.8 x	14.5 x
EV / EBITDA	-	787 x	-36.5 x	-	-28.5 x	177 x	41 x	33.2 x
EV / FCF	-	-97.1 x	-	-	-	212 x	35.4 x	38.1 x
FCF Yield	-	-1.03%	-	-	-	0.47%	2.83%	2.63%
Price to Book	-	36.4 x	-	-	-	11.3 x	9.43 x	8.45 x
Nbr of stocks (in thousands)	29,658	30,034	30,332	37,892	38,185	38,195	-	-
Reference price ³	24,100	65,600	36,600	17,300	23,050	30,200	30,200	30,200
Announcement Date	3/6/20	2/3/21	2/9/22	3/17/23	3/18/24	-	-	-

¹KRW in Million²KRW in Billions³KRW

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	4.369	43.47	3.903	-	4.951	44	69.5	71
EBITDA ¹	-	2.469	-30.18	-	-30.9	6	25	31
EBIT ¹	-	1.58	-31.5	-	-32.66	5	24	29
Operating Margin	-	3.64%	-807.04%	-	-659.58%	11.36%	34.53%	40.85%
Earnings before Tax (EBT)	-	1.293	-	-	-	-	-	-
Net income	-	-4.357	-	-24.43	-	-	-	-
Net margin	-	-10.02%	-	-	-	-	-	-
EPS	-890.0	-155.0	-	-763.0	-	-	-	-
Free Cash Flow ²	-	-20,014	-	-	-	5,000	29,000	27,000
FCF margin	-	-46,039.79%	-	-	-	11,363.64%	41,726.62%	38,028.17%
FCF Conversion (EBITDA)	-	-	-	-	-	83,333.33%	116,000%	87,096.77%
FCF Conversion (Net income)	-	-	-	-	-	-	-	-
Dividend per Share	-	-	-	-	-	-	-	-
Announcement Date	3/6/20	2/3/21	2/9/22	3/17/23	3/18/24	-	-	-

¹KRW in Billions²KRW in Million

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	-	-	-	-	-	-	-	-
Net Cash position ¹	-	26.5	7.64	-	-	93	128	125
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Free Cash Flow ²	-	-20,014	-	-	-	5,000	29,000	27,000
ROE (net income / shareholders' equity)	-	-4.05%	-	-	-	3%	21.4%	20%
ROA (Net income/ Total Assets)	-	-3.08%	-	-	-	3.2%	6.8%	16.3%
Assets	-	141.5	-	-	-	-	-	-
Book Value Per Share ³	-	1,800	-	-	-	2,673	3,203	3,574
Cash Flow per Share ³	-	-612.0	-	-	-	199.0	361.0	835.0
Capex	-	2.13	-	-	-	-	-	1
Capex / Sales	-	4.91%	-	-	-	-	-	1.41%
Announcement Date	3/6/20	2/3/21	2/9/22	3/17/23	3/18/24	-	-	-

¹KRW in Billions²KRW in Million³KRW

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

30,200 KRW

Average target price

46,500 KRW

Spread / Average Target

+53.97%

	1st Jan change	Capi.
OSCOTEC INC.	+31.02%	796M
MERCK KGAA	+9.85%	72.5B
KYOWA KIRIN CO. LTD.	+13.69%	9.11B
SK BIOPHARMACEUTICALS CO., LTD.	-12.85%	5.07B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+60.16%	5.01B
YUHAN CORPORATION	+1.60%	3.85B
BETTA PHARMACEUTICALS CO., LTD.	-19.20%	2.46B
INDIVIOR PLC	+18.65%	2.44B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+24.62%	2.27B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-27.46%	2.26B